Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 388,600 shares, a growth of 3,947.9% from the September 30th total of 9,600 shares. Approximately 10.5% of the company’s shares are sold short. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is currently 0.3 days.

Bio-Path Stock Performance

Shares of Bio-Path stock opened at $1.10 on Friday. The business has a 50-day moving average of $1.05 and a 200 day moving average of $1.82. Bio-Path has a 12 month low of $0.85 and a 12 month high of $14.42.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the previous year, the firm earned ($10.60) EPS. Research analysts predict that Bio-Path will post -6.2 EPS for the current year.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.74% of the company’s stock.

Wall Street Analysts Forecast Growth

BPTH has been the subject of a number of recent analyst reports. StockNews.com began coverage on Bio-Path in a research report on Wednesday. They set a “sell” rating for the company. Roth Mkm restated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a report on Monday, July 8th.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.